NORTHPHARM LTD

Company Registration Number:
SC777004 (Scotland)

Unaudited abridged accounts for the year ended 31 July 2024

Period of accounts

Start date: 26 July 2023

End date: 31 July 2024

NORTHPHARM LTD

Contents of the Financial Statements

for the Period Ended 31 July 2024

Balance sheet
Notes

NORTHPHARM LTD

Balance sheet

As at 31 July 2024


Notes

2024


£
Fixed assets
Intangible assets: 3 977,194
Tangible assets: 4 43,024
Total fixed assets: 1,020,218
Current assets
Stocks: 99,780
Debtors:   156,859
Cash at bank and in hand: 266,610
Total current assets: 523,249
Creditors: amounts falling due within one year:   (78,854)
Net current assets (liabilities): 444,395
Total assets less current liabilities: 1,464,613
Creditors: amounts falling due after more than one year:   (1,347,500)
Total net assets (liabilities): 117,113
Capital and reserves
Called up share capital: 100
Profit and loss account: 117,013
Shareholders funds: 117,113

The notes form part of these financial statements

NORTHPHARM LTD

Balance sheet statements

For the year ending 31 July 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 10 January 2025
and signed on behalf of the board by:

Name: UMAR RAZZAQ
Status: Director

The notes form part of these financial statements

NORTHPHARM LTD

Notes to the Financial Statements

for the Period Ended 31 July 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

NORTHPHARM LTD

Notes to the Financial Statements

for the Period Ended 31 July 2024

2. Employees

2024
Average number of employees during the period 9

NORTHPHARM LTD

Notes to the Financial Statements

for the Period Ended 31 July 2024

3. Intangible Assets

Total
Cost £
Additions 977,194
At 31 July 2024 977,194
Net book value
At 31 July 2024 977,194

NORTHPHARM LTD

Notes to the Financial Statements

for the Period Ended 31 July 2024

4. Tangible Assets

Total
Cost £
Additions 47,804
At 31 July 2024 47,804
Depreciation
Charge for year 4,780
At 31 July 2024 4,780
Net book value
At 31 July 2024 43,024